TRANSITION SERVICES AGREEMENT by and between ALKERMES, INC. and MURAL ONCOLOGY, INC. Dated as of November 13, 2023Transition Services Agreement • November 15th, 2023 • Mural Oncology PLC • Pharmaceutical preparations • Delaware
Contract Type FiledNovember 15th, 2023 Company Industry JurisdictionThis TRANSITION SERVICES AGREEMENT (this “Agreement”), dated as of November 13, 2023 (the “Effective Date”), is entered into by and between Alkermes, Inc., a Pennsylvania corporation and wholly owned indirect subsidiary of Alkermes plc (“Alkermes US”), and Mural Oncology, Inc., a Delaware corporation and, following the Separation, a wholly owned direct subsidiary of Mural Oncology plc (“Mural US”). “Party” or “Parties” means Alkermes US or Mural US, individually or collectively, as the case may be.
TRANSITION SERVICES AGREEMENT by and between ALKERMES, INC. and MURAL ONCOLOGY, INC. Dated as of [•], 2023Transition Services Agreement • September 22nd, 2023 • Mural Oncology PLC • Pharmaceutical preparations • Delaware
Contract Type FiledSeptember 22nd, 2023 Company Industry JurisdictionThis TRANSITION SERVICES AGREEMENT (this “Agreement”), dated as of [•], 2023 (the “Effective Date”), is entered into by and between Alkermes, Inc., a Pennsylvania corporation and wholly owned indirect subsidiary of Alkermes plc (“Alkermes US”), and Mural Oncology, Inc., a Delaware corporation and, following the Separation, a wholly owned direct subsidiary of Mural Oncology plc (“Mural US”). “Party” or “Parties” means Alkermes US or Mural US, individually or collectively, as the case may be.
TRANSITION SERVICES AGREEMENT by and between MURAL ONCOLOGY, INC. and ALKERMES, INC. Dated as of [•], 2023Transition Services Agreement • September 22nd, 2023 • Mural Oncology PLC • Pharmaceutical preparations • Delaware
Contract Type FiledSeptember 22nd, 2023 Company Industry JurisdictionThis TRANSITION SERVICES AGREEMENT (this “Agreement”), dated as of [•], 2023 (the “Effective Date”), is entered into by and between Mural Oncology, Inc., a Delaware corporation and, following the Separation, a wholly owned direct subsidiary of Mural Oncology plc (“Mural US”), and Alkermes, Inc., a Pennsylvania corporation and wholly owned direct subsidiary of Alkermes plc (“Alkermes US”). “Party” or “Parties” means Mural US or Alkermes US, individually or collectively, as the case may be.